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Abstract
Background: DNA repair deficient tumor cells have been shown to accumulate high levels of
DNA damage. Consequently, these cells become hyper-dependent on DNA damage response
pathways, including the CHK1-kinase-mediated response. These observations suggest that DNA
repair deficient tumors should exhibit increased sensitivity to CHK1 inhibition. Here we offer
experimental evidence in support of this hypothesis.
Results: Using isogenic pairs of cell lines differing only in the Fanconi Anemia (FA) DNA repair
pathway, we showed that FA deficient cell lines were hypersensitive to CHK1  silencing by
independent siRNAs as well as CHK1 pharmacologic inhibition by Gö6976 and UCN-01. In parallel,
an siRNA screen designed to identify gene silencings synthetically lethal with CHK1 inhibition
identified genes required for FA pathway function. To confirm these findings in vivo, we
demonstrated that whole zebrafish embryos, depleted for FANCD2 by a morpholino approach,
were hypersensitive to Gö6976. Silencing of FA genes led to hyper-activation of CHK1 and vice
versa. Furthermore, inactivation of CHK1 in FA deficient cell lines caused increased accumulation
of DNA strand and chromosomal breakages. These results suggest that the functions subserved by
CHK1 and the FA pathway mutually compensate in maintaining genome integrity. As CHK1
inhibition has been under clinical trial in combination with cisplatin, we showed that the FA specific
tumoricidal effect of CHK1 inhibition and cisplatin was synergistic.
Conclusion: Taken together, these results suggest CHK1 inhibition as a strategy for targeting FA
deficient tumors.
Background
Human cancers exhibit genomic instability and height-
ened drug sensitivity due to underlying defects in DNA
repair or cell cycle regulation [1-3]. The specific pathways
affected may be predictive of the tumor's drug sensitivity
and clinical outcome. For some tumors, loss of one DNA
repair pathway may result in hyper-dependence on a sec-
ond, compensatory DNA repair pathway. Therapeutic
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gain may be achieved by inhibition of this second path-
way.
The Fanconi Anemia pathway (FA) is a DNA repair path-
way required for cellular response to DNA cross-linking
agents such as mitomycin C (MMC) and cisplatin
(CDDP). The thirteen known FA proteins cooperate in
this pathway, leading to the monoubiquitination of the
FANCD2/FANCI hetero-dimer, activating DNA crosslink
repair [4]. Disruption of any of the proteins in the FA
pathway, either by germline or somatic mutations, leads
to the characteristic cross-linker hypersensitivity and chro-
mosome instability.
Many human cancers have an acquired disruption of the
FA pathway. Loss of the pathway has been observed in
brain cancer [5], ovarian carcinomas [6], cervical cancer
[7], head and neck squamous cell carcinomas [8], and
myeloid leukemias [9]. It is estimated that approximately
15% of all tumors harbor defects in the FA pathway [10].
In most cases, disruption results from biallelic methyla-
tion and silencing of one of the upstream FA genes,
FANCF. Disruption of the pathway can also result from
loss of BRCA2/FANCD1 expression, as observed in breast,
ovarian, and pancreatic tumors [10]. FA pathway deficient
tumors have recently been shown to be hyper-dependent
on a different DNA repair mechanism mediated by the
ATM kinase [11].
DNA repair through the FA pathway occurs primarily dur-
ing S phase of the cell cycle. Accordingly, FA tumor cells
acquire extensive DNA damage in S phase. These lesions
persist throughout the remainder of the S and G2 phase,
ultimately activating the G2/M checkpoint [12,13]. As
such, increased accumulation of cells in the G2 phase of
the cell cycle is a useful diagnostic feature of FA cells [14].
This accumulation correlates with the hyper-activation of
a G2/M checkpoint [15]. We hypothesize that FA cells
may be hyper-dependent on this G2/M checkpoint for via-
bility, since the checkpoint activation allows for the repair
of damaged DNA prior to mitosis.
The G2/M checkpoint of FA cells is regulated by the check-
point kinase, CHK1. CHK1 is activated by the ATR kinase
in response to DNA damages that stall replication fork
progression [16]. Upon activation, CHK1 functions by
phosphorylating Cdc25c, thereby halting the transition of
cells from G2 to M phase. Several CHK1 inhibitors are cur-
rently undergoing clinical trials as anti-neoplastic agents
[17,18]. These inhibitors are used largely in combination
with other DNA damaging agents including cisplatin [19],
fluorouracil [20], topotecan [21], and cytarabine [22].
Given the hyper-dependence of FA cells on the G2/M
checkpoint and the critical role of CHK1 in mediating this
checkpoint, we hypothesized that FA pathway deficient
tumors may be hypersensitive to CHK1 inhibition. Here,
we provide both in vitro and in vivo evidence that FA defi-
cient tumor cells are hypersensitive to inhibition of
CHK1, particularly when combined with cisplatin ther-
apy. The functions of these two pathways appear compen-
satory as inactivation of one leads to the hyper-activation
of the other. Taken together, these results suggest that the
integrity of the FA pathway represents a critical molecular
determinant of therapeutic response to CHK1 inhibition.
Results
FA pathway deficient cells are hypersensitive to CHK1 
inhibitors
FA cells accumulate in the G2 phase of the cell cycle, and
this accumulation is more pronounced after exposure to
exogenous DNA damaging agents [12]. The G2 accumula-
tion results, at least in part, from hyperactive CHK1 activ-
ity. This CHK1 hyperactivity may serve as a compensatory
mechanism for FA pathway deficiency. We reasoned
therefore that FA cells may be hypersensitive to CHK1
inhibition.
To test this hypothesis, we first examined the effect of
CHK1 silencing on the clonogenic survival of a FANCA
deficient cell line (GM6914) and its isogenic FANCA cor-
rected cell line (GM6914+A). Two distinct siRNAs
directed against CHK1 were tested in order to minimize
the likelihood of off-target effects (Figure 1A). With both
siRNAs, GM6914 (FANCA-deficient) cells were more sen-
sitive to CHK1 knockdown than the corrected cell line.
For CHK1-1 siRNA, the uncorrected cells exhibited only
42% viability after siRNA treatment (lane 3), while the
corrected cells showed 76% viability (lane 4). For CHK1-
2 siRNA, the uncorrected cells exhibited only 40% viabil-
ity after siRNA treatment (lane 5), whereas the corrected
cells showed 65% viability (lane 6). Of note, we previ-
ously reported that FA deficient cell lines are hypersensi-
tive to ATM inhibition [11]. The magnitude of the FA
specific killing by CHK1 silencing reported here is compa-
rable to that observed for ATM silencing.
A Western blot was performed to confirm silencing of
CHK1 and better characterize the molecular nature of the
FA-CHK1 interaction (Figure 1A, Western blot). Silencing
with the CHK1-1 siRNA resulted in decreased CHK1 pro-
tein levels and increased phospho-H2Ax levels, particu-
larly in the FANCA deficient cells (lanes 3, 4). This result
suggests that the CHK1 and FA genes function in compen-
satory manner to maintain genome integrity.
Consistent with this model, the GM6914+FANCA cor-
rected cell line demonstrated enhanced FANCD2 monou-
biquitination following knockdown of CHK1 (L/S ratio of
0.9 vs 0.2), suggesting that the FA pathway is activated fol-Molecular Cancer 2009, 8:24 http://www.molecular-cancer.com/content/8/1/24
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lowing loss of CHK1 function (Figure 1B compare lanes 2
and 4 in the Western blot).
FA deficient cells are hypersensitive to pharmacologic 
CHK1 inhibition
To further safeguard against siRNA "off-target" effects, we
wished to confirm our observation using a pharmacologic
inhibitor of CHK1. Recent studies have indicated that
some of the small molecular inhibitors initially thought
to be CHK1 specific possessed activities against related
kinases [23]. As more small molecule kinase inhibitors are
subjected to detailed scrutiny, it is becoming increasingly
clear that absolute specificity remains elusive. Neverthe-
less, specificity of each inhibitor class has improved with
each generation of refinement. We searched the literature
for a CHK1 inhibitor with high specificity and identified
Gö6976 [24]. In a study where the specificities of 65 com-
monly used small molecule kinase inhibitors were tested
for inhibition of a panel of 80 purified protein kinases,
Gö6976 was shown to exhibit relative specificity against
CHK1. At sub-micro molar concentration, the specificity
of Gö6976 against CHK1 was over 40-fold that of CHK2,
100-fold that of MAPKAP-K2, and 30-fold that of MKK1
and MKK2 [23].
We, therefore, examined FANCA, FANCG, and FANCD2
mutant and paired isogenic corrected cell lines and com-
pared the sensitivity of the lines to Gö6976 (Figure 1B). In
each case, the FA pathway deficient cell line was more sen-
sitive to Gö6976. The LC50 for the FA deficient cell lines
ranged 250–500 nM whereas the LC50 for the isogenic FA
proficient cell lines ranged 1–2 uM. The magnitude of the
FA specific killing by Gö6976 reported here is comparable
to that observed for ATM inhibitor KU55933.
While CHK1-1 siRNA, CHK1-2 siRNA, and Gö6976 each
likely possess activities unrelated to CHK1 function, the
recapitulation of the same phenotype using these three
independent agents in multiple cell lines suggests CHK1
to be the most likely target.
FA pathway deficient tumor cells are hypersensitive to 
CHK1 inhibition
To test our hypothesis that FA deficient tumor lines are
hyper-dependent on CHK1 function, we tested a pair of
isogenic FA proficient and deficient tumor cell lines with
regard to sensitivity to CHK1 siRNA and Gö6976. The
2008 ovarian carcinoma line is deficient in FA pathway
function due to methylation of the FANCF  promoter
region [6]. This cell line can be functionally corrected with
an exogenously expressed FANCF gene to create the 2008F
line. Indeed, the FA deficient 2008 cell line was found to
be more sensitive to Gö6976 than the FANCF comple-
mented 2008F at all doses (50 to 500 nM) tested (Figure
1C, lanes 3–8).
Since Gö6976 inhibits kinases unrelated to CHK1
[23,24], we wished to confirm our results with another
inhibitor that has a relatively high specificity for CHK1
but exhibits a different specificity profile with regard to
non-CHK1 kinases [23]. Such an inhibitor would unlikely
recapitulate the effect of Gö6976 if the underlying mech-
anism was independent of CHK1. We selected UCN-01
for this purpose. Comparable to that observed for
Gö6976, the FA deficient 2008 cell line was hyper-sensi-
tive to UCN-01 relative to the FA restored 2008F cell line
(Figure 1C, lanes 9–12). This finding supported our
hypothesis that FA deficient tumor cells are hyper-
dependent on CHK1 for cell viability.
While Gö6976 and UCN-01 exhibited differential specifi-
city for non-CHK1 related kinases for the most part, both
inhibited Protein Kinase C alpha (PRKCα) and Protein
Kinase C beta 1 (PRKCβ1) in addition to CHK1 at the con-
centrations tested in this study [23,25]. To exclude PRKCα
and PRKCβ1 inhibition as the cause underlying the FA
specific tumor killing of Gö6976 and UCN-01, we tested
the effect of independent siRNAs directed against PRKCα
and PRKCβ1. The specificity of both siRNAs was validated
in a previous study [26]. At > 80% silencing efficiency,
neither siRNAs caused preferential killing of the 2008 line
FA cells are hypersensitive to CHK1 silencing and inhibition Figure 1 (see previous page)
FA cells are hypersensitive to CHK1 silencing and inhibition. (A) Response of isogenic FANCA deficient (GM6914) 
and proficient (GM6914+A) lines to CHK1 silencing. Cells were treated with siRNA targeting GFP (bars 1 and 2), CHK1-1 
siRNA (bars 3 and 4) or CHK1-2 siRNA (bars 5 and 6). Western blot analysis: GM6914 (lanes 1, 3); GM6914+A (lanes 2, 4). (B) 
Response of FANCA (GM6914), FANCD2 (PD20 cells), and FANCG (PD326) deficient lines to CHK1 inhibition by Gö6976. Cells 
were exposed to Gö6976 for 24 hrs and then incubated for 5 days before viability was determined by the Cell Titer-Glo assay 
(Promega). (C) A FA pathway deficient ovarian cancer cell line is hyper-sensitive to CHK1 inhibition. A 14 day colony count 
assay comparing the response of FANCF deficient 2008 ovarian cancer cells (bars 1, 3, 5, 7, 9, 11, 13, 15, and 17) versus FANCF 
corrected 2008F cells (bars 2, 4, 6, 8, 10, 12, 14, 16, and 18) after treatment with Gö6976, UCN-01, and siRNA against CHK1, 
PRKCα, PRKCβ1, and GFP. Viability of each target siRNA treated cell line was calculated as a percentage of the GFP siRNA 
treated cells. (D) Disruption of the FA pathway sensitizes cells to Gö6976. HeLa cells were transfected with the various siR-
NAs for 24 hrs followed by treatment by either Gö6976 (500 nM) or DMSO. Each bar represents the ratio of cellular viability 
between Gö6976 and DMSO treatment.Molecular Cancer 2009, 8:24 http://www.molecular-cancer.com/content/8/1/24
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relative to the 2008F line. In contrast, an siRNA directed
against CHK1 caused preferential killing of the 2008 line
relative to the 2008F (Figure 1C, lanes 13–18).
While the Gö6976, UCN-01, CHK1 siRNA, PRKCα, and
PRKCβ1 data sets were each individually imperfect, com-
bined they offer strong support for the hypothesis that FA
deficient tumors are hyper-dependent on CHK1 function.
Overall, the FA specific tumoricidal effect of CHK1 silenc-
ing/inhibition was comparable to those that we previ-
ously reported for ATM silencing/inhibition [11].
Knockdown of FA genes sensitizes cells to CHK1 inhibition
To demonstrate that hypersensitivity to CHK1 inhibition
is the result of FA pathway deficiency rather than any spe-
cific FA genes, we next screened a number of siRNAs
directed against several FA gene products for their ability
to enhance the cytotoxicity of Gö6976 (Figure 1D). To
this end, HeLa cells were transfected with two independ-
ent siRNAs directed against several FA genes (A, C, D1,
D2, E, F, G) for 24 hrs followed by treatment by either
Gö6976 or DMSO. For each siRNA, cell viability was
determined as a ratio of the Gö6976 treated cells relative
to the DMSO treated cells (Figure 1D). For instance, the
viability of the HeLa cell treated with scrambled siRNA
and Gö6976 was approximately 75% that of cells treated
with scrambled siRNA and DMSO. Using this ratio, we
observed that cells transfected with siRNA directed against
the FA genes exhibited significantly increased sensitivity
to Gö6976 relative to the scrambled sequence siRNA. Oli-
gonucleotides targeting BRCA1  and  CHK1  were also
included as controls. Consistent with its role as a CHK1
inhibitor, siRNA against CHK1 did not further sensitize
cells to Gö6976 relative to the scrambled siRNA. Simi-
larly, knockdown of BRCA1, a gene required for CHK1
function in the G2/M checkpoint [27], did not further
sensitize cells to Gö6976 relative to scrambled siRNA. In
sum, inactivation of the FA pathway by siRNA depletion
(6 FA genes tested, each gene tested with 2 independent
siRNAs) consistently augmented the cytotoxicity of
Gö6976.
Synthetic lethal screen with Gö6976 revealed a 
predominance of FA genes
Having observed the selective cytotoxicity of Gö6976 on
various FA deficient cell lines, we initiated a genetic screen
to identify other DNA repair defects that may predispose
to such selective cytotoxicity. To this end, we screened the
QIAGEN DNA repair siRNA library that consists of 460
pre-optimized siRNAs targeting 230 DNA repair/damage
response genes. In this library, each gene target was repre-
sented by two distinct, pre-optimized siRNAs. We
searched for genetic silencings that are selectively toxic to
HeLa cells when combined with Gö6976 treatment. The
screening process is outlined in Figure 2A and detailed in
the Methods. In brief, each gene target is evaluated based
on the average effect of the two targeting siRNAs deter-
mined in two independent screens. Using this measure-
ment, the top 30 targets that caused selective toxicity
when combined with Gö6976 treatment are shown in Fig-
ure 2B. One third of this list consisted genes required for
the integrity of the FA pathway, including FANCA,
FANCC, FANCD2, FANCD1, FANCF, FANCE, FANCG,
RPA1, RPA2, and RPA3 [28]. The probability of such clus-
tering by chance is less than 0.0001 (Fisher Exact Test). As
such, the result of this unbiased genetic screen represents
a powerful confirmation of the increased reliance of
CHK1 function in FA deficient cells.
Gö6976 induces DNA damage in FA pathway deficient 
cells
FA cells are characterized by DNA breakage accumulation
in S phase. These breakages persist throughout S and G2
phase of the cell cycle until activation of the G2/M check-
point. We hypothesize that CHK1 mediated G2/M check-
point is required for repairing some of these DNA breaks.
In this framework, CHK1 inactivation in FA deficient cells
caused elevated level of DNA strand break that ultimately
led to cell death.
To test this hypothesis, we treated GM6914 (FANCA-defi-
cient) and corrected GM6914A cells with Gö6976 for 24
hrs then assessed DNA breakage by measuring histone
H2AX phosphorylation (Western blot, Figure 3A). The FA
pathway deficient GM6914 (FANCA-deficient) cell line
demonstrated increased H2AX phosphorylation at a con-
centration range of 100 nM–1 μM of inhibitor (lanes 3–
6). The corrected GM6914A cell line demonstrated
increased H2AX phosphorylation only at the highest con-
centration of Gö6976 (lane 12, 1 μM). These data indicate
that the FA pathway deficient cells accumulate DNA dam-
age at a lower level of CHK1 inhibition than the corrected
line.
As an independent means of confirming the above
hypothesis, we scored for metaphase spread chromo-
somal breaks in isogenic FA proficient and deficient cells
treated with the CHK1-1 siRNA or Gö6976. Since the
unrepaired strand breaks in FA cells are converted into
chromosomal breaks during mitosis [29], we anticipate
that CHK1 silencing should result in increased chromo-
somal breakage accumulation in FA pathway deficient
cells. Indeed, the FA deficient GM6914 cell line treated
with the CHK1 targeted siRNA demonstrated more chro-
mosomal breakage (32 breaks per 50 cells) than the cor-
rected line (18 breaks per 50 cells) (Figure 3B). Similarly,
PD326 (FANCD2 deficient) and EUFA130 (FANCE defi-
cient) cells demonstrated more chromosomal breakage
than paired cDNA-corrected cell lines following 24 hr
treatment with Gö6976 (Figure 3C). Together these dataMolecular Cancer 2009, 8:24 http://www.molecular-cancer.com/content/8/1/24
Page 6 of 16
(page number not for citation purposes)
siRNA oligonucleotide targets that are synthetically lethal with CHK1 inhibition by Gö6976 Figure 2
siRNA oligonucleotide targets that are synthetically lethal with CHK1 inhibition by Gö6976. (A) Schematic for 
identification of siRNA oligonucleotides that exhibited selective toxicity when combined with CHK1 inhibition by Gö6976 (i.e. 
synthetic lethality). Cells were plated on day 1. On day 2, each well was transfected with an siRNA oligonucleotide directed 
toward one DNA damage response/repair gene. On day 3, one set of cells was treated with Gö6976 (Calbiochem) at a con-
centration of 500 nM. The other set was treated with DMSO. On day 6, the viability of the cells in each well was measured 
using the Cell Titer-Glo Luminescent Cell Viability Assay kit (Promega). (B) The top 30 gene targets from the genetic screen. 
The top 30 targets where both independent siRNAs caused toxicity when combined with Gö6976 treatment are shown in Fig-
ure 2B. Viability and standard deviation calculation are calculated as described in Methods. Genes integral to FA pathway func-
tion are indicated in red.
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indicate that CHK1 is required to prevent the accumula-
tion of sporadic chromosomal breaks in FA pathway defi-
cient cells.
Cell death after Gö6976 treatment in FA pathway 
deficient cells
Next we asked how Gö6976 treatment resulted in loss of
viability in FA pathway deficient cells. HeLa cells were
treated with siRNA targeting FANCA  or a GFP  control
sequence. Thereafter, cells were treated with Gö6976 for
48 hrs. Cell death was assessed by flow cytometry using
annexin V and propidium iodide (PI) staining.
Approximately 7% of the cells transfected with the GFP
control sequence exhibited PI uptake (Figure 4A).
Gö6976 treatment (500 nM) after GFP  transfection
caused a small increase in the amount of PI uptake (to
13%) relative to GFP transfection alone. About 25% of the
cells exhibit PI uptake after FANCA depletion. Percent of
cells with PI uptake was increased to 74% when combin-
ing FANCA depletion and Gö6976 treatment. This data
represents another independent verification of the syn-
thetic lethality between FA deficiency and CHK1 inactiva-
tion.
The annexin V staining was not significantly different
between the various conditions tested and the positive
control (cisplatin). As such, definitive conclusions regard-
ing the mode of cell death after CHK1 inactivation could
not be drawn.
Disruption of the FA pathway activates CHK1 and results 
in a G2 accumulation
In view of the hypersensitivity of FA cells to Gö6976, we
predicted that CHK1 may be activated in the absence of
the FA pathway. To test this hypothesis, we knocked down
FANCA or BRCA2 (FANCD1) in HeLa cells using siRNA
and assessed CDC25C phosphorylation, as a measure of
CHK1 function. In each case CHK1 was activated by
knockdown of the FA gene (Figure 4B, lanes 3 and 5, anti-
pCHK1 immunoblot). Addition of Gö6976 inhibited the
phosphorylation of CDC25C, indicating abrogation of
CHK1 function in the FA pathway deficient cells (Figure
4B, lanes 4 and 6). In addition, phosphorylation of CHK1
on serine 317 was observed following Gö6976 treatment
(lanes 2, 4, 6), indicating increased ATR activity. This
observation is consistent with other studies indicating an
increase in ATR-mediated phosphorylation of CHK1 fol-
lowing inhibition of CHK1 kinase activity [30]. Also, as
predicted, siRNA knockdown of FANCA or BRCA2 in
HeLa cells resulted in an increase in the G2/M percentage
of cells (Figure 4C), consistent with a compensatory
increase in CHK1 activation of the G2/M checkpoint in
these cells.
FANCD2 knockdown sensitizes zebrafish embryos to 
Gö6976
To ensure that the hypersensitivity of FA deficient cells to
CHK1 inhibition was not an artifact of our cell model sys-
tems, we used an in vivo, whole organism approach (Fig-
ure 5). We have previously described a FANCD2
knockdown model in zebrafish using a morpholino
approach [31]. We treated zebrafish embryos with an
increasing concentration of the FANCD2 morpholino
after 1 uM Gö6976 treatment. The specificity of Gö6976
for CHK1 inhibition in the in vivo zebrafish model was
previously demonstrated by our group [32]. In the
absence of FANCD2 morpholino, treatment with 1 uM of
Gö6976 yielded no detectable phenotype ([32] and Figure
5). However, a combined loss of the FA pathway and
CHK1 function resulted in enhanced lethality of zebrafish
embryos. This result confirms the synthetic lethality
between FA pathway and CHK1 inactivation in an in vivo
model.
CHK1 inhibition causes increased cell death in FA pathway deficient cells Figure 3 (see previous page)
CHK1 inhibition causes increased cell death in FA pathway deficient cells. (A) Western blots comparing H2AX 
phosphorylation and FANCD2 monoubiquitination in FANCA mutant GM6914 cells (lanes 1 to 6) versus FANCA corrected 
GM6914+A cells (lanes 7 to 12). Each cell line was treated for 24 hrs with Gö6976 in a dose range from 0 to 1000 nM as indi-
cated. The L/S ratio represents the ratio of the upper monoubiquitinated (Long) form of FANCD2 compared to the unmodi-
fied form (Short) as measured by densitometry. Each blot was probed for vinculin to ensure equal protein loading. (B) A 
graphical representation of the number of chromosomal breaks per cell as measured by metaphase spreads 72 hrs after treat-
ment with a GFP targeted control siRNA (Bars 1 and 2) or a CHK1 targeted siRNA (Bars 3 and 4). Bars 1 and 3 represent 
GM6914 and bars 2 and 4 represent the isogenic corrected GM6914+A cell line. (C) A graphical representation of the number 
of chromosomal breaks per cell as measured by metaphase spreads 48 hrs after treatment with Gö6976 (Bars 3, 4, 7 and 8) or 
DMSO only (Bars 1, 2, 5 and 6). Bars 1 and 3 represent FANCG mutant PD326 cells and bars 2 and 4 represent isogenic cor-
rected cells. Bars 5 and 7 represent FANCE mutant (EUFA130) cells and bars 6 and 8 represent isogenic EUFA130+E corrected 
cells. Fifty metaphase spreads were counted per experiment. Each experiment was repeated three times with similar results. 
Representative experiments are shown.Molecular Cancer 2009, 8:24 http://www.molecular-cancer.com/content/8/1/24
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FA specific tumoricidal effect of CHK1 inhibition and 
cisplatin was synergistic
The selectivity of CHK1 inhibition for FA defective tumor
is modest (approximately two-fold). However, CHK1
inhibition is under clinical trial in combination with cis-
platin and other DNA damaging agents. Many of these
DNA damaging agents, including cisplatin are also shown
to have FA specific tumoricidal activities [6]. We, there-
fore, tested the effect of combining CHK1 inhibition with
cisplatin treatment. As shown in Figure 6A, the FA defi-
cient 2008 line was hypersensitive to cisplatin treatment
and CHK1 inhibition by Gö6976. In response to either
Analysis of the mechanism of cell death and the cell cycle effect of CHK1 inhibition in FA pathway deficient cells Figure 4
Analysis of the mechanism of cell death and the cell cycle effect of CHK1 inhibition in FA pathway deficient 
cells. (A) An annexin V/PI staining cell death assay to assess mode of cell death in HeLa cells treated with siRNA targeting GFP, 
FANCA, and Gö6976. Twenty-four hrs after siRNA transfection, the cells were treated with 500 nM Gö6976 or DMSO for an 
additional 48 hrs. Cells were then collected and subjected to annexin V/PI staining. Cells were also treated with cisplatin 10 μM 
for 24 hrs as a positive apoptotic control. (B) FA pathway knockdown activates CHK1 and accumulation of cells in the G2 
phase of the cell cycle. Western blots measuring phosphorylation of CDC25C, CHK1, and monoubiquitination of FANCD2 in 
HeLa cells treated with control siRNA (lanes 1 and 2), siRNA targeting FANCA (lanes 3 and 4), and siRNA targeting BRCA2 
(lanes 5 and 6). Cells were either treated for 24 hrs with Gö6976 (lanes 2, 4, 6) or DMSO control (lanes 1, 3, 5). Membranes 
were probed for vinculin to ensure equal loading. (C) Cell cycle analysis of HeLa cells treated with control GFP targeted 
siRNA, FANCA targeted siRNA or BRCA2 targeted siRNA followed by Gö6976 or DMSO control for 24 hrs. The mitotic pop-
ulation was assessed by measuring histone H3 phosphorylation by flow cytometry. Populations of cells at G1 (2N), S (between 
2N and 4N), G2/M (4N), G2 (4N with no histone H3 staining), and M (4N with phosphohistone H3 staining) are given as a per-
centage of total cell population. Values are calculated from duplicate experiments.
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Gö6976 or cisplatin, the 2008 cells exhibited a two-fold
increase in sensitivity relative to the 2008F. When sub-
jected to a combined CHK1 inhibition and cisplatin treat-
ment, this differential sensitivity was magnified to
approximately ten-fold. When fit into the Chou-Talalay
mutually nonexclusive modal [33], the Combination
Index (CI) was 0.7, supporting a synergistic effect.
Combination of ATM and CHK1 inhibition induces 
synergistic killing of FA deficient tumor cells
We previously demonstrated that Fanconi Anemia (FA)
pathway deficient tumor cells are hypersensitive to inhibi-
tion of the Ataxia Telangiectasia Mutated (ATM) kinase
(29). Having observed the synergistic FA specific effect of
CHK1 inhibition and cisplatin treatment, we wished to
determine whether such synergism could be achieved by
combining ATM and CHK1 inhibition. To this end, we
combined the lowest tumoricidal dose of the ATM inhib-
itor, KU-55933 (10 uM) with the lowest toxic doses of the
CHK1 inhibitor, Gö6976 (50 and 100 nM). Consistent
with our previous report, the 2008 cells were hypersensi-
tive to KU-55933 (10 uM), relative to the 2008F cells (Fig-
ure 6B). Similarly, the 2008 cell line was consistently
more sensitive to Gö6976 than 2008F. At the doses tested,
the FA selective tumoricidal effects of ATM and CHK1
inhibition were comparable. When the two inhibitors
were combined, the FA specific cytotoxicity was increased
to approximately 5-fold. When fit into the Chou-Talalay
mutually nonexclusive modal [33], the Combination
Index (CI) was 0.9, supporting a synergistic effect.
Discussion
We and others have previously demonstrated that epige-
netic silencing of the FA pathway occurs in sporadic adult
tumors [3]. It is estimated that approximately 15% of all
cancers harbor defects in the FA pathway [10]. These
tumors, like the FA deficient cells derived from Fanconi
Anemia patients demonstrate increased accumulation of
FANCD2 depleted Zebra Fish embryos are selectively sensitive to Gö6976 Figure 5
FANCD2 depleted Zebra Fish embryos are selectively sensitive to Gö6976. A graphical representation of zebrafish 
embryo viability following depletion of FANCD2 using an increasing concentration of a specific morpholino and treatment with 
Gö6976 (bars 2, 4, 6, 8, 10 and 12) or DMSO control (bars 1, 3, 5, 7, 9 and 11). Representative photographs of FANCD2 
depleted embryos 24 hrs after Gö6976 treatment are shown. Gö6976 was used at a concentration of 0.5 uM.
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Figure 6 (see legend on next page)
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DNA strand breaks. This accumulation is attributable to
defective DNA repair and DNA damage response [12,13].
As a result of these defects, compensatory repair mecha-
nisms become activated, including the CHK1 mediated
G2/M checkpoint. We hypothesize that FA deficient
tumors are hyper-dependent on these pathways for viabil-
ity. It follows that therapeutic gain can be achieved by
selective inhibition of these compensatory pathways. We
tested this paradigm by examing the effect of CHK1 inhi-
bition in FA deficient cells.
We used four approaches to demonstrate that tumor cells
deficient in the FA pathway are hypersensitive to CHK1
inhibition: 1) siRNA knockdown of FA genes 2) FA gene
mutant and corrected isogenic lines; 3) a morpholino
knockdown of FANCD2 in a zebrafish model; and 4)
pharmacologic inhibition using two CHK1 inhibitors,
Gö6976 and UCN-01. The siRNA approach most closely
resembles epigenetic silencing of a normal FA gene as it
occurs in a proportion of sporadic tumors. The mutant FA
gene lines represent the situation in heterozygous carriers
of a mutation where loss of heterozygosity results in
malignancy. The zebrafish model allowed us to investi-
gate the importance of CHK1 in vivo. The pharmacologic
inhibition experiments are most directly translatable to
clinical trials.
As with all small molecule kinase inhibitors, the specifi-
city of Gö6976 for CHK1 is not absolute. It is well-known
that additional kinases are affected by Gö6976 [23]. How-
ever, our data strongly support that the FA specific tumo-
ricidal effect of Gö6976 is mediated through CHK1
inhibition. First, this effect of Gö6976 is recapitulated by
two distinct siRNAs directed against CHK1 in independ-
ent cell lines (Figures 1A and 1B). Second, siRNA knock-
down of CHK1  in a Gö6976 treated cell yield results
comparable to Gö6976 treatment or CHK1  silencing
alone (Figures 1C and 1D). Third, the effect of Gö6976 is
recapitulated by another CHK1 inhibitor (UCN-01) that,
for the most part, has a distinct specificity profile against
non-CHK1 kinases. Finally, siRNA silencing of the two
non-CHK1 targets shared by UCN-01 and Gö6976
(PRKCα and PRKCβ1) failed to cause FA specific tumor
killing. While there may be inherent properties of Gö6976
that restricts its translation to clinical trial, newer classes
of more specific Chk1 inhibitors are becoming available
and undergoing clinical trials [34,35]. The insights
derived in this study may be helpful in the design of such
trials.
There are inherent limitations to CHK1 inhibition as a
therapeutic strategy. Cells completely depleted for CHK1
using siRNA technology undergo severe DNA damage and
die [30]. In addition CHK1 knockout mice are not viable
[36]. Our data support a model in which therapeutic effect
is derived from partial depletion of CHK1, rather than
complete inhibition. In particular, FA pathway deficient
tumor cells have a greater requirement for CHK1 function
than DNA repair proficient cells. Consistent with other
groups, we observed DNA breakage and toxicity at high
doses of CHK1 inhibition in DNA repair competent cells
[30]. FA pathway deficient cells, however, demonstrate
hypersensitivity to Gö6976 at concentrations that caused
little detectable phenotype in FA proficient cells (100–500
nM). These data support the existence of a therapeutic
window that could be exploited in treating DNA repair
deficient cancers with CHK1 inhibitors, while sparing tox-
icity in normal, DNA repair proficient cells.
Our results indicate that the selectivity of CHK1 inhibi-
tion for FA deficient tumor as a monotherapy is modest.
However, it is one that can be exploited when combined
with other modalities of treatment. For instance, we pre-
viously showed that cisplatin induced DNA lesions
require activation of the FA pathway for repair. Conse-
quently, FA deficient tumors are hypersensitive to cispla-
tin [6]. When CHK1 inhibition is combined with cisplatin
treatment, the FA selective tumoricidal effect is increased
by an order of magnitude (Figure 6A), yielding an effect
that is likely clinically pertinent. As another example, we
previously demonstrated that ATM and FA genes function
in a compensatory manner to maintain genome integrity.
The FA deficient tumor cells are, thus, hypersensitive to
ATM inhibition [11]. While the selectivities of ATM inhi-
FA specific tumoricidal activity of CHK1 inhibition in combination with Cisplatin (CDDP) treatment or ATM inhibition Figure 6 (see previous page)
FA specific tumoricidal activity of CHK1 inhibition in combination with Cisplatin (CDDP) treatment or ATM 
inhibition. (A) Seven day viability assay comparing the response of FANCF deficient 2008 ovarian cancer cells (bars 1, 3, 5, 7) 
versus FANCF corrected 2008F cells (bars 2, 4, 6, 8) to 25 uM CDDP (bars 3 and 4), and 25 uM CDDP + 100 nM Gö6976 (bars 
11 and 12). Bars 1 and 2 represent DMSO only controls. When fit into the Chou-Talalay mutually nonexclusive modal [33], the 
Combination Index (CI) is 0.7, mathematically supporting a synergistic effect. (B) 7 day viability assay comparing the response 
of FANCF deficient 2008 ovarian cancer cells (bars 1, 3, 5, 7, 9, 11) versus FANCF corrected 2008F cells (bars 2, 4, 6, 8, 10, 12) 
to 10 uM KU-55933 (bars 3 and 4), 50 nM Gö6976 (bars 5 and 6), 100 nM (bars 7 and 8), 10 uM KU-55933 + 50 nM Gö6976 
(bars 9 and 10), and 10 uM KU-55933 + 50 nM Gö6976 (bars 11 and 12). Bars 1 and 2 represent DMSO only controls. When 
fit into the Chou-Talalay mutually nonexclusive modal [33], the Combination Index (CI) is 0.9, mathematically supporting a syn-
ergistic effect.Molecular Cancer 2009, 8:24 http://www.molecular-cancer.com/content/8/1/24
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bition and CHK1 inhibition for FA defective tumor are
low individually, the effect of combining them is synergis-
tic, yielding an effect that is likely pertinent clinically (Fig-
ure 6B).
The hypersensitivity of FA deficient cells to CHK1 and
ATM inhibition suggests a framework for cancer therapy
by manipulation of DNA repair. Inhibition of any one of
these three pathways (FA, CHK1, and ATM) results in an
increased accumulation of DNA strand breaks and chro-
mosomal breakage that is exacerbated by the inhibition of
a second pathway ([11] and Figures 1A, 3A). This inhibi-
tion translates into a modest reduction in cell survival
([11] and Figures 1A–D). Simultaneous inactivation of all
three pathways (Figure 6B), however, results in a loss of
cell survival that is synergistic when compared to inactiva-
tion of any two pathways ([11] and Figure 6B). These
results suggest that FA, ATM, and CHK1 are functionally
compensatory in the repair of DNA damage. Inactivation
of any one or two pathway(s) leads to DNA damage accu-
mulation, triggering compensatory activation of the
remaining pathway(s). This compensatory activation
accounts for the modest effect of CHK1 (or ATM) inhibi-
tion on FA deficient cells. Significant effect is achieved
only with simultaneous inactivation of all three compen-
satory pathways. This framework suggests that an under-
standing of the network of compensatory repair pathways
is a pre-requisite for meaningful manipulation of DNA
repair as a therapeutic strategy.
From a biomarker perspective, our study suggests that
monitoring of FA pathway activation can serve as a meas-
ure of CHK1 inhibition in vivo. We showed that CHK1
inhibitors or siRNAs triggered FANCD2 monoubiquitina-
tion in FA proficient cell lines (Figures 3A and 4B).
Accordingly, in clinical trials, it may be useful to follow FA
pathway activation as a pharmacodynamic marker of
CHK1 inhibition in vivo. Activation of FANCD2 monou-
biquitination in peripheral blood lymphocytes or tumor
cells during clinical trials may allow an internal measure-
ment of CHK1 inhibition in vivo. Additionally, given the
hypersensitivity of FA deficient tumors to CHK1 inhibi-
tion in the context of cisplatin therapy, profiling the integ-
rity of the FA pathway may be warranted in clinical trials
involving such combination.
Conclusion
In sum, we have identified CHK1 inhibition as a strategy
for targeting FA deficient tumor cells, especially when
combined with cisplatin treatment or ATM inhibition.
While synergy between CHK1 inhibition and cisplatin has
been documented both in vivo and in vitro previously [34],
this report represents the first to demonstrate significant
augmentation of this synergistic effect in FA deficient
tumors. Future research should focus on the identification
of DNA repair/damage response pathways absent in spe-
cific tumor types and the critical compensatory pathways
activated. With such understanding, appropriate combi-
nations of cytotoxic chemotherapy and DNA damage
response/DNA repair inhibitors could be tailored for max-
imal therapeutic efficacy.
Methods
Cell Lines and Culture Conditions
The HeLa, PD326 (FANCG-deficient), GM6914 (FANCA-
deficient), PD20 (FANCD2-deficient) derived cell lines
have been previously described [37-39]. There were no
differences between the cloning efficiency of FA proficient
and deficient cells. Cells were cultured in DMEM medium
(Gibco) supplemented with 15% fetal calf serum and 1
μg/ml puromycin. The EUFA130 (FANCE-deficient) and
2008 ovarian tumor line derived have also been previ-
ously described [6,40] and were cultured in RPMI
medium (Gibco) supplemented with 15% fetal calf serum
and 1 μg/ml puromycin. Cisplatin (Sigma), UCN-01
(Sigma), and Gö6976 (Calbiochem) were dissolved in
DMSO at 1 mg/ml and used at the specified concentra-
tions. KU-55933 (Sigma) was prepared as 10 mmol/L
stock solution in DMSO.
siRNA Library screen
The QIAGEN DNA damage response DNA repair siRNA
library targeting 230 DNA damage response genes was
purchased in seven 96-well plates. Each plate also con-
tained 2 GFP-targeted siRNAs, 2 LacZ-targeted siRNAs,
and 16 wells containing no siRNA as controls. HeLa cells
were seeded in 2 sets of 7 black 96 well plates (BD bio-
sciences) at a count of 1000 cells per well in 80 ul of
DMEM medium with 15% FCS. Cells from each set were
individually transfected with siRNA from the Qiagen DNA
repair library as previously described [11]. After 72 hrs
one set of cells was treated with Gö6976 (Calbiochem) at
a concentration of 500 nM. The other set was treated with
DMSO alone. Forty-eight hrs later, the viability of the cells
in each well was measured using the Cell Titer-Glo Lumi-
nescent Cell Viability Assay kit (Promega). The experi-
ment was performed twice to allow statistical analysis of
the targets. The corrected viability for each siRNA oligonu-
cleotide was calculated as a percentage of the mean viabil-
ity of the 16 non-siRNA treatment control wells on each
plate. The corrected viability of the Gö6976 treated cell
line was divided by the corrected viability of the DMSO
control treated cell line for each gene target to calculate
the relative viability for each respective gene target. The
mean relative viability between the Gö6976 and DMSO
treated cell line for each gene target, along with the stand-
ard error of the mean (SEM), was calculated from four
individual corrected viability values that represent dupli-
cate results from the two different oligonucleotides on
each plate targeting a particular gene.Molecular Cancer 2009, 8:24 http://www.molecular-cancer.com/content/8/1/24
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Zebrafish data
1-cell stage wild-type zebrafish embryos (AB strain) were
injected with fancd2 MO [31]. At 24 hrs post-fertilization
(hpf), embryos were dechorionated and incubated in
standard embryo medium containing 1% DMSO and 1
μM Gö6976 (or DMSO as control). Viability was assayed
at 6 dpf in three independent experiments. Forty-eight hpf
and 6 dpf embryos were photographed with a Nikon Dig-
ital Sight DS-U1 camera mounted on a Nikon SMZ1500
microscope.
Cell Viability Assay
All viability experiments were done in triplicates and
repeated three times. For the Gö6976 and the drug com-
bination studies, cells were seeded in 96-well plates at a
density of 250–500 cells per well on day 1. The cells were
treated with various combinations of 10 uM KU-55933
(Sigma-Aldrich), 50 nM Gö6976 (Calbiochem), 100 nM
Gö6976, 25 uM cisplatin (Sigma-Aldrich), or DMSO
(negative control) on day 2. Seven days after treatment,
cellular viability was measured using the Cell Titer-Glo
Luminescent Cell Viability Assay kit (Promega). The mean
cellular viability and standard error measurement were
calculated as a percentage of the untreated controls from
three separate experiments.
For viability assays following CHK1 or control GFP tar-
geted siRNA transfection, cellular viability was measured
using the Cell Titer-Glo Luminescent Cell Viability Assay
kit (Promega) 7 days after transfection. Cellular viability
for each well was calculated as a percentage of the mean
viability of GFP targeted siRNA treated cells. The mean cel-
lular viability and standard error of the mean was calcu-
lated and plotted using GraphPad Prism version 3
(GraphPad Software, San Diego California USA). Each
viability experiment was repeated at least three times.
Cell Cycle analysis and P-H3 staining
Cell cycle profiles were measured by flow cytometry as
previously described [41]. For p-H3 measurement, cells
were washed with phosphate-buffered saline (PBS), and
fixed in 70% ethanol for 24 hrs. Cells were then permea-
bilized in 1 ml of 0.25% Triton X-100 in PBS, and incu-
bated on ice for 15 min. After centrifugation, the cell
pellet was resuspended in 100 μl of PBS containing 1%
bovine serum albumin (BSA) and phosphohistone H3
polyclonal antibody (1:100) (Upstate Biotechnology,
Lake Placid, N.Y.) and incubated for 3 hrs at room temper-
ature. The cells were then washed with PBS containing 1%
BSA and incubated with fluorescein isothiocyanate-conju-
gated goat anti-rabbit immunoglobulin G antibody (Jack-
son ImmunoResearch Laboratories, Inc., West Grove, Pa.)
diluted at a ratio of 1:30 in PBS containing 1% BSA. After
30 mins the cells were washed in PBS and resuspended in
25 μg of propidium iodide (PI) (Sigma, St. Louis, Mo.)/ml
and 0.1 mg of RNase A (Sigma)/ml in PBS for 30 minutes
at room temperature. The samples were analyzed using a
Becton Dickinson (San Jose, Calif.) FACSCalibur flow
cytometer/cell sorter.
Cell Death Assay
Cells were seeded at 50% confluence in 100 mm dishes
and treated for 48 hrs with 500 nM Gö6976 or 8 μl DMSO
control. Cell death was measured using the Annexin V-
FITC Apoptosis Detection Kit I (BD Pharmingen).
Clonogenic Assays
All clonogenic experiments were done in triplicate and
repeated three times. The 2008 and 2008F cell lines were
each seeded at a density of 500 cells in a 100 mm diameter
dish and after 6 hrs treated with Gö6976 at 50, 100 or 500
nM for 24 hrs or DMSO. After 10 days, monolayers were
washed once with PBS and fixed for 10 min at room tem-
perature in 10% (vol/vol) methanol and 10% (vol/vol)
acetic acid. Adherent colonies were stained for 5 to 10 min
at room temperature with 1% (wt/vol) crystal violet
(Sigma) in methanol. The mean colony count and stand-
ard error of the mean were calculated.
siRNA Oligonucleotides
The following siRNA target sequences were used: GFP (5'-
AACACTTGTCACTACTTTCTC-3'), CHK1-1 (5'-AAGAAG-
CAGTCGCAGTGAAGA-3'),  CHK1-2  (5'-CCACCTCAT-
CATAACAACAAT-3'),  BRCA2  (Dharmacon, Smartpool
reagent M-003462-00-0005) and FANCA (Santa Cruz sc-
40567). Other siRNAs used were taken from the QIAGEN
DNA damage response DNA repair or the kinome librar-
ies. These sequences will be available upon request. For all
experiments, greater than 80% knockdown was achieved
with each siRNA as gauged by qPCR.
siRNA oligonucleotide verification
Cell lines were transfected with 20 nM of siRNA oligonu-
cleotides using HiPerfect transfection reagent (QIAGEN,
Valencia, CA) following the manufacturer's instructions.
The QIAGEN QuantiTect SYBR Green RT-PCT Kit was
used to quantify the efficiency of gene silencing per man-
ufacturer's instructions. The expression of each gene was
normalized using the housekeeping gene GAPDH. Knock-
down for each siRNA was compared to a scrambled siRNA
control. Data were analyzed with a BioRad iCycler.
Immunoblotting
Cells were lysed with 1× sample buffer (50 mM Tris-HCl
(pH 6.8), 0.6% 2-mercaptoethanol, and 2% sodium
dodecyl sulfate (SDS)) and boiled for 20 min. The lysate
was added to 1× loading buffer (50 mM Tris-HCl (pH
6.8), 0.6% 2-mercaptoethanol, 2%SDS, 20% glycerol)
and subjected to polyacrylamide SDS gel electrophoresis.
For FANCA, FANCF, FANCD2 or vinculin, 10 μg of pro-Molecular Cancer 2009, 8:24 http://www.molecular-cancer.com/content/8/1/24
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tein was run on a 3–8% tris-acetate gradient gel (Invitro-
gen). For the detection of all other proteins 10 μg was run
on a 4–12% bis-tris gel (Invitrogen). Following electro-
phoresis, proteins were transferred to a PVDF membrane
using a submerged transfer apparatus (Bio-Rad). Mem-
branes were then probed with the following antibodies:
anti-FANCD2 (1:1000; Santa Cruz Cat#sc-20022), anti-
FANCA (1:1000; [42]) anti-FANCF (1:1000, [43], anti-
BRCA2 (1:1000, Calbiochem Cat#OP95), anti-
phosphoH2AX Ser 139 (1:2000; Upstate Cell Signaling
Solutions Cat#07-164), anti-phopsho-317-CHK1 (1:500;
Cell Signaling Cat#2344), anti-CHK1(G-4) (Santa Cruz
Cat#8480), antiphospho-CDC25C (1:1000; Cell Signal-
ing Cat#4901), anti-GAPDH (1:3000; Abcam
Cat#ab9484), and anti-vinculin (1:2000; Santa Cruz
Cat#sc25336).
Cytogenetic Analysis
Chromosomal breakage was analyzed on metaphase
spreads as previously described [44]. Fifty spreads were
scored for each experiment, and each experiment was
repeated twice. PD326, GM6914 and EUFA130 cells and
isogenic corrected cells were treated with Gö6976 500 nM
for 48 hrs prior to analysis. In addition, GM6914 and iso-
genic corrected cells were treated with GFP  siRNA or
CHK1 targeted siRNA for 72 hrs prior to analysis.
Abbreviations
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